Transcription activator-like effector nuclease-mediated transduction of exogenous gene into IL2RG locus

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Matsubara, Yohei ^a   Chiba, Tomoki ^a   Kashimada, Kenichi ^a   Morio, Tomohiro ^a   Takada, Shuji ^b   Mizutani, Shuki ^a   Asahara, Hiroshi ^a,b,c,d  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDONUCLEASE; IL2RG PROTEIN, HUMAN; INTERLEUKIN 2 RECEPTOR GAMMA; MESSENGER RNA;

DOUBLE STRANDED DNA BREAK; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENE VECTOR; GENETICS; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN GENOME; JURKAT CELL LINE; METABOLISM; MOLECULAR GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EDITING; SEQUENCE HOMOLOGY; SOUTHERN BLOTTING;

BASE SEQUENCE; BLOTTING, SOUTHERN; DNA BREAKS, DOUBLE-STRANDED; ENDONUCLEASES; FLOW CYTOMETRY; GENETIC VECTORS; GENOME, HUMAN; HOMOLOGOUS RECOMBINATION; HUMANS; INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT; JURKAT CELLS; MOLECULAR SEQUENCE DATA; MUTAGENESIS, INSERTIONAL; MUTATION; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA EDITING; RNA, MESSENGER; SEQUENCE HOMOLOGY, NUCLEIC ACID;

EID: 84901455425     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep05043     Document Type: Article

References (35)

1. Noguchi, M. et al. Interleukin-2 receptor gamma chain mutation results in Xlinked severe combined immunodeficiency in humans. Cell 73, 147-157 (1993). (Pubitemid 23115456)
2. Sugamura, K. et al. The interleukin-2 receptor gamma chain: its role in the multiple cytokine receptor complexes and T cell development in XSCID. Annu. Rev. Immunol. 14, 179-205 (1996). (Pubitemid 26130182)
3. Cavazzana-Calvo, M. et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288, 669-672 (2000). (Pubitemid 30241569)
4. Gaspar, H. B. et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 364, 2181-2187 (2004). (Pubitemid 40018447)
5. Hacein-Bey-Abina, S. et al. Efficacy of gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 363, 355-364 (2010).
6. Hacein-Bey-Abina, S. et al. A Serious Adverse Event after Successful Gene Therapy for X-Linked Severe Combined Immunodeficiency. N. Engl. J. Med. 348, 255-256 (2003). (Pubitemid 36077924)
7. Hacein-Bey-Abina, S. et al. LMO2-Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1. Science 302, 415-419 (2003). (Pubitemid 37296260)
8. Hacein-Bey-Abina, S. et al. Insertional oncogenesis in 4 patients after retrovirusmediated gene therapy of SCID-X1. J. Clin. Invest. 118, 3132-3142 (2008).
9. Kohn, D. B., Sadelain, M. & Glorioso, J. C. Occurrence of leukaemia following gene therapy of X-linked SCID. Nat. Rev. Cancer. 3, 477-488 (2003). (Pubitemid 37328836)
10. Bushman, F. D. Retroviral integration and human gene therapy. J. Clin. Invest. 117, 2083-2086 (2007). (Pubitemid 47219550)
11. Deichmann, A. et al. Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy. J. Clin. Invest. 117, 2225-2232 (2007). (Pubitemid 47219567)
12. Schwarzwaelder, K. et al. Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo. J. Clin. Invest. 117, 2241-2249 (2007). (Pubitemid 47219569)
13. Yáñez, R. J. & Porter, A. C. Therapeutic gene targeting. Gene Ther. 5, 149-159 (1998). (Pubitemid 28077741)
14. Chapman, J. R., Taylor, M. R. & Boulton, S. J. Playing the end game: DNA doublestrand break repair pathway choice. Mol. Cell 47, 497-510 (2012).
15. Kim, Y. G., Cha, J. & Chandrasegaran, S. Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain. Proc. Natl. Acad. Sci. U S A. 93, 1156-1160 (1996). (Pubitemid 26052857)
16. Bibikova, M., Beumer, K., Trautman, J. K. & Carroll, D. Enhancing gene targeting with designed zinc finger nucleases. Science 300, 764 (2003). (Pubitemid 36532104)
17. Urnov, F. D. et al. Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 435, 646-651 (2005). (Pubitemid 40825505)
18. Urnov, F. D., Rebar, E. J., Holmes, M. C., Zhang, H. S. & Gregory, P. D. Genome editing with engineered zinc finger nucleases. Nat. Rev. Genet. 11, 636-646 (2010).
19. Christian, M. et al. Targeting DNA double-strand breaks with TAL effector nucleases. Genetics 186, 757-761 (2010).
20. Miller, J. C. et al. A TALE nuclease architecture for efficient genome editing. Nat. Biotechnol. 29, 143-148 (2011).
21. Bedell, V. M. et al. In vivo genome editing using a high-efficiency TALEN system. Nature 491, 114-118 (2012).
22. Zu, Y. et al. TALEN-mediated precise genome modification by homologous recombination in zebrafish. Nat. Methods 10, 329-331 (2013).
23. Schneider, U., Schwenk, H. U. & Bornkamm, G. Characterization of EBV-genome negative ''null'' and ''T'' cell lines derived from children with acute lymphoblastic leukemia and leukemic transformed non-Hodgkin lymphoma. Int. J. Cancer 19, 621-626 (1977). (Pubitemid 8094638)
24. Akbar, A. N. et al. Interleukin-2 receptor common gamma-chain signaling cytokines regulate activated T cell apoptosis in response to growth factor withdrawal: selective induction of anti-apoptotic (bcl-2, bcl-xL) but not proapoptotic (bax, bcl-xS) gene expression. Eur. J. Immunol. 26, 294-299 (1996).
25. Ding,Q. et al. Enhanced efficiency of human pluripotent stem cell genome editing through replacing TALENs with CRISPRs. Cell Stem Cell 12, 393-394 (2013).
26. Bousso, P. et al. Diversity, functionality, and stability of the T cell repertoire derived in vivo from a single human T cell precursor. Proc. Natl. Acad. Sci. U S A. 97, 274-278 (2000). (Pubitemid 30055821)
27. Nagai, T. et al. A variant of yellow fluorescent protein with fast and efficient maturation for cell-biological applications. Nat. Biotechnol. 20, 87-90 (2002). (Pubitemid 34044921)
28. Grez, M., Reichenbach, J., Schwäble, J., Seger, R., Dinauer, M. C. & Thrasher, A. J. Gene therapy of chronic granulomatous disease: the engraftment dilemma. Mol. Ther. 19, 28-35 (2011).
29. Puck, J. M. et al. Mutation analysis of IL2RG in human X-linked severe combined immunodeficiency. Blood 89, 1968-1977 (1997). (Pubitemid 27132112)
30. Yusa, K. et al. Targeted gene correction of a1-antitrypsin deficiency in induced pluripotent stem cells. Natur 478, 391-394 (2011).
31. Dahlem, T. J. et al. Simple methods for generating and detecting locus-specific mutations induced with TALENs in the zebrafish genome. PLoS Genet. 8, e1002861 (2012).
32. Sander, J. D. et al. ZiFiT (Zinc Finger Targeter): an updated zinc finger engineering tool. Nucleic Acids Res. 38, W462-468 (2010).
33. Cermak, T. et al. Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting. Nucleic Acids Res. 39, e82 (2011).
34. Sakuma, T. et al. Efficient TALEN construction and evaluation methods for human cell and animal applications. Genes Cells 18, 315-326 (2013).
35. Reyon, D. et al. FLASH assembly of TALENs for high-throughput genome editing. Nat. Biotechnol. 30, 460-465 (2012).